NASDAQ:MTFB - MOTIF BIO PLC/S Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.11
+0.30 (1.20%)
Get New MOTIF BIO PLC/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MTFB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MTFB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for MOTIF BIO PLC/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.11.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in MOTIF BIO PLC/S. This rating has held steady since July 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/7/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/6/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/15/2019Northland SecuritiesSet Price TargetBuy$5.00High
i
Rating by Carl Byrnes at Northland Securities
3/26/2019Northland SecuritiesReiterated RatingBuy$5.00Low
i
2/25/2019HC WainwrightDowngradeBuy ➝ NeutralLow
i
Rating by Ram Selvaraju at HC Wainwright
10/9/2018HC WainwrightSet Price TargetBuy$32.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/14/2018HC WainwrightSet Price TargetBuy$32.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/8/2018HC WainwrightSet Price TargetBuy$32.00Low
i
Rating by Ram Selvaraju at HC Wainwright
6/11/2018HC WainwrightReiterated RatingBuy$32.00High
i
4/19/2018HC WainwrightReiterated RatingBuy$32.00High
i
4/16/2018Northland SecuritiesInitiated CoverageOutperformLow
i
3/29/2018GabelliReiterated RatingHoldHigh
i
Rating by K. Kedra at Gabelli
12/29/2017WBB SecuritiesInitiated CoverageSell$7.00Low
i
12/22/2017Seaport Global SecuritiesReiterated RatingBuyHigh
i
Rating by V. Bernardino at Seaport Global Securities
10/11/2017HC WainwrightSet Price TargetBuy$32.00N/A
i
Rating by R. Selvaraju at HC Wainwright
10/4/2017HC WainwrightBoost Price TargetBuy$25.00 ➝ $32.00High
i
Rating by R. Selvaraju at HC Wainwright
9/20/2017HC WainwrightReiterated RatingBuy$25.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/9/2017HC WainwrightSet Price TargetBuy$25.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
4/24/2017Rodman & RenshawBoost Price TargetBuy ➝ Buy$16.00 ➝ $25.00Low
i
1/9/2017Rodman & RenshawInitiated CoverageBuy$16.00N/A
i
(Data available from 2/28/2016 forward)
MOTIF BIO PLC/S logo
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.
Read More

Today's Range

Now: $0.11
$0.10
$0.12

50 Day Range

MA: $0.10
$0.10
$0.11

52 Week Range

Now: $0.11
$0.08
$11.50

Volume

867,698 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of MOTIF BIO PLC/S?

The following Wall Street analysts have issued research reports on MOTIF BIO PLC/S in the last twelve months: Zacks Investment Research.
View the latest analyst ratings for MTFB.

What is the current price target for MOTIF BIO PLC/S?

0 Wall Street analysts have set twelve-month price targets for MOTIF BIO PLC/S in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for MOTIF BIO PLC/S in the next year.
View the latest price targets for MTFB.

What is the current consensus analyst rating for MOTIF BIO PLC/S?

MOTIF BIO PLC/S currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MTFB.

What other companies compete with MOTIF BIO PLC/S?

How do I contact MOTIF BIO PLC/S's investor relations team?

MOTIF BIO PLC/S's physical mailing address is 201 TEMPLE CHAMBERS 3-7 TEMPLE AVENUE, LONDON X0, EC4Y0DT. The company's listed phone number is 212-210-6248 and its investor relations email address is [email protected] The official website for MOTIF BIO PLC/S is www.motifbio.com.